144 related articles for article (PubMed ID: 18782009)
1. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
[TBL] [Abstract][Full Text] [Related]
2. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4633-7. PubMed ID: 16782336
[TBL] [Abstract][Full Text] [Related]
3. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
Stupple PA; Batchelor DV; Corless M; Dorr PK; Ellis D; Fenwick DR; Galan SR; Jones RM; Mason HJ; Middleton DS; Perros M; Perruccio F; Platts MY; Pryde DC; Rodrigues D; Smith NN; Stephenson PT; Webster R; Westby M; Wood A
J Med Chem; 2011 Jan; 54(1):67-77. PubMed ID: 21128663
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Xu GG; Guo J; Wu Y
Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
[TBL] [Abstract][Full Text] [Related]
5. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
7. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
[TBL] [Abstract][Full Text] [Related]
8. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
Lemoine RC; Petersen AC; Setti L; Baldinger T; Wanner J; Jekle A; Heilek G; deRosier A; Ji C; Rotstein DM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1674-6. PubMed ID: 20137937
[TBL] [Abstract][Full Text] [Related]
10. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.
Swinney DC; Beavis P; Chuang KT; Zheng Y; Lee I; Gee P; Deval J; Rotstein DM; Dioszegi M; Ravendran P; Zhang J; Sankuratri S; Kondru R; Vauquelin G
Br J Pharmacol; 2014 Jul; 171(14):3364-75. PubMed ID: 24628038
[TBL] [Abstract][Full Text] [Related]
11. Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
van der Ryst E; Heera J; Demarest J; Knirsch C
Ann N Y Acad Sci; 2015 Jun; 1346(1):7-17. PubMed ID: 25962411
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel CCR5 antagonist lead compound through fragment assembly.
Liu Y; Zhou E; Yu K; Zhu J; Zhang Y; Xie X; Li J; Jiang H
Molecules; 2008 Oct; 13(10):2426-41. PubMed ID: 18830165
[TBL] [Abstract][Full Text] [Related]
13. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Kim MB; Giesler KE; Tahirovic YA; Truax VM; Liotta DC; Wilson LJ
Expert Opin Investig Drugs; 2016 Dec; 25(12):1377-1392. PubMed ID: 27791451
[TBL] [Abstract][Full Text] [Related]
14. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
Metz M; Bourque E; Labrecque J; Danthi SJ; Langille J; Harwig C; Yang W; Darkes MC; Lau G; Santucci Z; Bridger GJ; Schols D; Fricker SP; Skerlj RT
J Am Chem Soc; 2011 Oct; 133(41):16477-85. PubMed ID: 21942640
[TBL] [Abstract][Full Text] [Related]
15. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
Kazmierski WM; Anderson DL; Aquino C; Chauder BA; Duan M; Ferris R; Kenakin T; Koble CS; Lang DG; McIntyre MS; Peckham J; Watson C; Wheelan P; Spaltenstein A; Wire MB; Svolto A; Youngman M
J Med Chem; 2011 Jun; 54(11):3756-67. PubMed ID: 21539377
[TBL] [Abstract][Full Text] [Related]
16. A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
Kawai Y; Tsukamoto S; Ito J; Akimoto K; Takahashi M
Chem Pharm Bull (Tokyo); 2011; 59(9):1110-6. PubMed ID: 21881254
[TBL] [Abstract][Full Text] [Related]
17. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
18. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
